Innate Pharma SA (FR:IPH) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Innate Pharma SA has unveiled promising data from its TELLOMAK Phase 2 study, highlighting the potential of lacutamab to improve the quality of life for patients with cutaneous T-cell lymphoma. The study shows significant alleviation of symptoms such as severe itching and skin infections, offering hope for those with limited treatment options.
For further insights into FR:IPH stock, check out TipRanks’ Stock Analysis page.
